Basecamp Research Raises $140M From Nvidia, Anthropic Fund to Mine Nature's Genomes for Drug Design

Basecamp Research has closed a $140 million funding round with backing from Nvidia and Anthropic's Anthology Fund, money the London company will use to expand an AI operation built on genetic material collected from rainforests, oceans and hot springs. The startup applies those datasets to the design of antibiotics and tools for cell therapies, positioning itself at the intersection of machine learning and synthetic biology.

The pitch rests on a claim its technical leadership makes bluntly: biology is a much harder domain for AI than language. CTO Philip Lorenz, speaking with THE DECODER, argued that the messy, interdependent systems inside a cell do not yield to the pattern-matching that has driven progress in text models. Where a language model can absorb billions of words scraped from the web, biological training data must be physically gathered, sequenced and verified, often from remote field sites.

That data problem is the company's real product. Basecamp Research sends teams to sample organisms in environments that have not been catalogued, then pairs the sequences with metadata about where and how the organisms live. The resulting corpus is proprietary, which matters in a field where public genomic databases are large but unevenly annotated. Nvidia's participation signals interest in the compute demands of protein and molecule generation, while Anthropic's Anthology Fund ties the round to a major AI lab's investment arm.

Lorenz also pushed back on how the field measures success. Strong benchmark scores, he said, do not guarantee that a designed molecule will work in a wet lab. That gap between computational metrics and experimental results has become a recurring frustration in AI-driven drug discovery, where promising in-silico candidates frequently fail assays or prove toxic. Basecamp Research's answer is to keep validation in-house, running its own laboratory work rather than handing designs off and hoping partners can make them function.

The raise puts Basecamp Research in a crowded but well-funded cohort of companies applying machine learning to drug discovery, alongside players using protein structure prediction and generative chemistry. What separates the bet here is sourcing: rather than training only on published data, the company is building an asset no competitor can simply download. The $140 million gives it room to scale collection and lab capacity before the results are judged on molecules rather than models.

What to watch next is whether the company can show clinical or preclinical candidates that clear real biological tests, not just scoring well on paper. The investors have bought into a long timeline, and the field's history is littered with AI-designed compounds that never left the bench. Basecamp Research's case will ultimately rest on whether evolution's own data can be turned into a medicine that works.